BIBLIOGRAPHY.
PAPERS AND BOOKS CITED IN TEXT.
Andersen MP. Lack of bioequivalence between disulfiram formulations. Exemplified by a tablet/effervescent tablet study. Acta Psychiatr Scand Suppl. 1992;369:31-5.
Annis HM, Peachey JE. The use of calcium carbimide in relapse prevention counselling: results of a randomized controlled trial. Br J Addict. 1992 Jan;87(1):63-72.
Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM,
Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3;295(17):2003-17.
Azrin NH, Sisson RW, Meyers R, Godley M. Alcoholism treatment by disulfiram and community reinforcement therapy. J Behav Ther Exp Psychiatry. 1982 Jun;13(2):105-12.
Azrin NH.. Disulfiram and behaviour therapy: a social-biochemical model of alcohol abuse and treatment. In: Brewer C. (Ed.) Treatment Options in Addiction - Medical Management of Alcohol and Opiate Abuse. London. Gaskell - Royal College of Psychiatrists. 1993:19-28.
Baffoe CS, Nguyen N, Boyd P, Wang W, Morris M, McConville C. Disulfiramloaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer. J Pharm Pharmacol. 2014 Dec 10. doi: 10.1111/jphp.12330.
Barrera E, Osinski W, Davidoff E The use of Antabuse (Tetraethylthiuramdisulphide) in chronic alcoholics, Am J Psychiat 1950;107, 8-13
Berglund M, Thelander S, Salaspuro M, Franck J, Andréasson S, Öjehagen A.
Bernier BE, Whitaker LR, Morikawa H. Previous ethanol experience enhances synaptic plasticity of NMDA receptors in the ventral tegmental area. J Neurosci. 2011 April 6; 31(14): 5205–5212.
Besson J, Aeby F, Kasas A et al Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alc Clin Exper Res 1998;22:573-579
Bhopal R, Tonks A. The role of letters in reviewing research (Editorial) BMJ 1994;308:158-223
Bickel WK, Rizzuto P, Zielony RD, Klobas J, Pangiosonlis P, Mernit R, Knight WF. Combined Behavioral and Pharmacological Treatment of Alcoholic Methadone Patients. J Subst Abuse. 1988-1989;1(2):161-71.
Billet SL. The use of Antabuse: An approach that minimises fear. Med Ann Dist Columb 1964;33:612-614
Bourne PG, Alford JA. Bowcock JZ. Treatment of skid-row alcoholics with Disulfiram Quart J Stud Alc 1966;27:42-.48.
Bowman N, Caravati EM, et al. Acute pneumonitis associated with nickel carbonyl exposure in the workplace. Clin Toxicol (Phila). 2017 Jul 28:1-3. doi: 10.1080/15563650.2017.1355057.
Brahen L, Henderson R, Capone T. Naltrexone treatment in a jail work-release program. J. Clin. Psychol. 1984;45, 49-52.
Brewer C. Perrett L. Brain damage due to alcohol consumption: a psychometric, air-encephalographic and EEG study. Brit J Addiction 1971;66:170-82
Brewer C, Smith J. Probation-linked supervised disulfiram in the treatment of habitual drunken offenders: results of a pilot study. BMJ. 1983;287:1282-83.
Brewer C. How effective is the standard dose of disulfiram? A review of the disulfiram-alcohol reaction in practice. British Journal of Psychiatry 1984;144:200-202
Brewer C. Patterns of compliance and evasion in treatment programmes which include supervised disulfiram. Alcohol Alc 1986;21:385-88
Brewer C. Treatment of cocaine abuse with monoamine oxidase inhibitors: a case report. Brit J Psychiat 1993;163: 815-6.
Brewer C. Long-term, high-dose disulfiram in the treatment of alcohol abuse. Brit J Psychiat 1993;163:687-689
Brewer C. Using disulfiram to maintain controlled drinking: A case report with a 14-year follow-up. Addiction Res 1996;3:231-235
Brewer C. Hardt F. Preventing disulfiram hepatitis in alcohol abusers: inappropriate guidelines and the significance of nickel allergy. Addiction Biol 1999;4:303-308
Brewer C. Supervised disulfiram is more effective in alcoholism than naltrexone or acamprosate - or even psychotherapy: How it works and why it matters. Adicciones. 2005. 17(4); 285-96
Brewer C. The deterrence issue. Lancet 2002;359:982.
Brewer C, Streel E. Learning the language of abstinence in addiction treatment: some similarities between relapse-prevention with disulfiram, naltrexone and other pharmacological antagonists and intensive 'immersion' methods of foreign language teaching. Substance Abuse, 2003; 24(3) 157-173.
Brewer C, Wong V-S. Naltrexone: a case report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addiction Biol 2004; 9: 81-7.
Brewer C. Editorial (bilingual): Harm-reduction for unwanted pregnancies and unwanted addictions: an instructive analogy. Adicciones, 2008;20(1):5-13
Brewer C, Streel E, Skinner M. Supervised disulfiram’s superior effectiveness in alcoholism treatment: ethical, methodological, and psychological aspects. Alcohol and Alcoholism, 2017, 1–7
Buchbinder R1, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009 Aug 6;361(6):557-68.
Burman S. The challenge of sobriety: natural recovery without treatment and self-help groups. J Subst Abuse. 1997;9:41-61.
Carroll KM, Ziedonis D, O’Malley S et al. Pharmacologic interventions for abusers of alcohol and cocaine: a pilot study of disulfiram versus naltrexone. Amer J Addict 1993;2:77-79.
Carroll KM, Nich C, Ball SA, McCance E. & Rounsaville B J. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998;93 (5), 713-728.
Cetin N, Suleyman B, Altuner D, Effect of disulfiram on ketamine-induced cardiotoxicity in rats. Int J Clin Exp Med. 2015 Aug 15;8(8):13540-7. eCollection 2015.
Chan KY. The Singapore naltrexone community-based project for heroin addicts compared with drugfree community-based program: the first cohort. J Clin Med 1996;3:87-92
Chen SC, Jeng KS,1, Lai MM.Zinc finger-containing cellular transcription corepressor ZBTB25 promotes influenza virus RNA transcription and is a target for zinc-ejector drugs. J Virol. 2017 Aug 2. pii: JVI.00842-17. doi: 10.1128/JVI.00842-17.
Chen Y-C, Lu R-B, Peng G-S, et al. (1999) Alcohol metabolism and cardio vascular response in an alcoholic patient homozygous for the ALDH2*2 variant gene allele. Alc Clin Exp Res 23:1853–60.
Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, Ritson B, Ropner R, Torley D. Disulfiram treatment of alcoholism. Br J Psychiatry. 1992 Jul;161:84-9.
Chick J. Safety issues concerning the use of disulfiram in treating alcohol dependence. Drug Safety. 1999;20;427-35.
Coffin PO, Santos GM, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki SL. Extended-Release Naltrexone for Methamphetamine Dependence among Men Who Have Sex with Men: A Randomized Placebo-Controlled Trial. Addiction. 22 July 2017 DOI: 10.1111/add.13950
COMBINE study. See: Anton RF. et al.
Cornish JW, Metzger D, Woody GW et al. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subs Abuse Treat 1997;14:529-534
Cuijpers P, Cristea IA. What if placebo effect explained all the activity of depression treatments? World Psychiat 2015; 14, 310-11.
Dalecki AG, Haeili M, Shah S, et al. Disulfiram and copper ions kill Mycobacterium tuberculosis in a synergistic manner. Antimicrob Agents Chemother. 2015 Jun 1. pii: AAC.00692-15. [Epub ahead of print]
Dandelot J-B, Dupuis M. L’Antabuse: ange ou demon? [review of disulfiram neuropathy] Le Concours Medical 1979: 101; 7666-73.
Dano P, Tammam D, Brosset C, Bregigeon M. [Peripheral neuropathies caused by disulfiram]. Rev Neurol (Paris). 1996 Apr;152(4):294-5. Soyka M. Relapse prevention in alcoholism; recent advances and future possibilities. CNS Drugs 1997;4:313-327.
Davidson K. Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status. Brit J Psychiat 1993;166, 199-204.
Davison A. Gene Therapy for Alcoholics. An interesting approach to curbing alcoholism is tested on rats. MIT Review. 2008, January 9th
Dawson DA, Grant BF, Stinson FS, Chou PS, Huang B, Ruan WJ. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction. 2005 Mar;100(3):281-92.
De Sousa A, de Sousa A. Naltrexone vs disulfiram A one year follow up of alcohol dependence treatment. Alcohol Alcohol. 2004 Nov-Dec;39(6):528-31
De Sousa A & de Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2005 Nov-Dec;40(6):545-8.
Diehl A, Ulmer L, Mutschler J, Herre H, Krumm B, Croissant B, Mann K, Kiefer F. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol. 2010 May-Jun;45(3):271-7. Brewer C. Disulfiram treatment for alcoholism. JAMA 1987;257:926.
Dodes L, Dodes Z. The sober truth. Debunking the bad science behind 12-step programs and the rehab industry. Boston. Beacon. 2015
Edwards G, Orford J, Egert S et al. Alcoholism: a controlled trial of ‘treatment’ and ‘advice’. Quart J Stud Alc 1977;38:1004-33.
Edwards G. Alcohol, the ambiguous molecule. London: Penguin. 2000 Edwards G, Orford J, Egert S et al. Alcoholism: a controlled trial of ‘treatment’ and ‘advice’. Quarterly J Stud Alc 1977;38:1004-33.
Ellis P, Dronsfield A. Antabuse’s diamond anniversary: Still sparkling on? Drug Alc Rev 2013;32, 342–344
Farmer RF, Seeley JR, Kosty DB, et al. No reliable evidence that emotional disorders are proximal antecedents, concomitants, or short-term consequences of first episode alcohol use disorders in a representative community sample. J Stud Alc Drugs, 78(2), 222–231 (2017).
Finney JW, Monahan SC. The cost-effectiveness of treatment for alcoholism: a second approximation. J Stud Alc. 1996;57:229-243.
Fletcher K. (2015) Disulfiram and the Zenalyser®: teaching an old dog new tricks. Alcohol Alcohol 50:255–6.
Fuller R, Branchey L, Brightwell D et al. Disulfiram treatment of alcoholism. JAMA 1986;256:1449-55.1986
Fuller R. Disulfiram treatment of alcoholism (letter) JAMA1987;257:927
Fuller R, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction 2004;99:21–4.
Fox R. Antabuse as an adjunct to psychotherapy in alcoholism. N Y J Med 1958;58:1540-1556.
Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971-1988) and report of a case. Alcohol Alcohol. 1989;24(5):429-37.
Galanter M. Network therapy for alcohol and drug abuse. London. Guilford. 1999.
Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005 Apr 6;293(13):1617-25.
Garland EL, Franken IH, Sheetz JJ, Howard MO. Alcohol attentional bias is associated with autonomic indices of stress-primed alcohol cue-reactivity in alcohol-dependent patients. Exp Clin Psychopharmacol. 2012 Jun;20(3):225-35.
Gessner P, Gessner N. Disulfiram and its metabolites. Buffalo, 1992.
Gitlow SE. Antabuse. In Gitlow SE, Peyser HS Alcoholism: a practical treatment guide. New York, Grune and Stratton, 1980; 273.
Gossop M. Limitations in the clinical use of all this neurobiological knowledge. Invited paper presented at 13th annual meeting International Society of Addiction Medicine. Oslo Sept 2011.
Grodzki M. Über äthylirte sulfoharnstoffe. Berl Deutsch Chem Ges 1881;14, 2754-2758.
Grover S, Basu D. The revival (or, rather, survival) of disulfiram. Addiction. 2004 Jun;99(6):785.
Hald J, Jacobsen E. A drug sensitising the organism to ethyl alcohol, Lancet, 1948, 252,1001- 1004.
Hart BW, Yourick JJ, Faiman MD. S-methyl-N,N-diethylthiolcarbamate: a disulfiram metabolite and potent rat liver mitochondrial low Km aldehyde dehydrogenase inhibitor. Alcohol. 1990 Mar-Apr;7(2):165-9.
Haynes SN. Contingency management in a municipally administered Antabuse program for alcoholics. J Behaviour Therapy Exper Psychiat 1973;4:31-32.
Hazai E, Vereczkey L, Monostory K. Reduction of toxic metabolite formation of acetaminophen. Biochem Biophys Res Commun. 2002 Mar 8;291(4):1089-94.
Higuchi S. (1994) Polymorphisms of ethanol metabolizing enzyme genes and alcoholism. Alcohol Alcohol Suppl 2:29–34.
Hodgson R. Resisting temptation: a psychological analysis. Brit J Addict. 1989;84.251-7.
Holder H, Longabaugh R, Miller W, Rubonis,A. The cost effectiveness of treatment for alcoholism: a first approximation. . J Stud Alc. 1991;52:517-540
Hoshi Y, Tani N, Tabata H, et al. Development of a therapeutic agent for menkes disease: solubilization of a copper-disulfiram complex. Yakugaku Zasshi. 2015;135(3):493-9
Ioannidis JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philos Ethics Humanit Med. 2008 May 27;3:14.
Iwashige T, Shibasaki M. [Disulfiram-induced delirium: a case report]. [Article in Japanese] Nihon Arukoru Yakubutsu Igakkai Zasshi. 2006 Dec;41(6):535-40.
Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl. 1992;369:15-26.
Kaaber K, Menne T, Veien N, Baadsgaard O. Some adverse effects of fisulfiram in the treatment of nickel-allergic patients. Dermatosen Beruf Umwelt 1987;38;209-11
Kalant H. What neurobiology cannot tell us about addiction. Addiction. 2009; 105; 780-9
Khan S, Singhal S, Mathur T. et al. Antifungal potential of disulfiram. Jpn J Med Mycol 2007;48.109-13
Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacol 2010 January; 35(1): 217–238.
Kragh H. From disulfiram to Antabuse: the invention of a drug. Bull. Hist. Chem, 2008,33(2) 82-88
Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Rüther E, Poser W, Ehrenreich H. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alc Clin Exp Res. 2006; 30(1):86-95.
Kranzler H, Wesson D, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alc Clin Exp Res. 2004 Jul;28(7):1051-9.
Kulig KC, Beresford T. Hepatitis C in Alcohol Dependence: Drinking versus Disulfiram J Addict Dis 2005. 24 (2) 77-89
Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2008 Jan-Feb;43(1):53-61.
Lappe C, Herholz SC, Trainor LJ, Pantev C. Cortical plasticity induced by short-term unimodal and multimodal musical training. J Neurosci. 2008 Sep 24;28(39):9632-9.
Larson E, Olincy A, Rummans TA, Morse RM. Disulfiram treatment of patients with both alcohol dependence and other psychiatric disorders: A review. Alc Clin Exp Res 1992;16:125-130.
Le Noury J et al. Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 2015;351:h4320
Lemere, F. The nature and significance of brain damage from alcoholism. Am J Psychiat 1956;113: 361–362.
Lemoyne S, Raemaekers J, Daems J, Heytens L. Delayed and prolonged coma after acute disulfiram overdose. Acta Neurol Belg. 2009 Sep;109(3):231-4.
Lenz VH. Zur ursache der fehlenden Antabus-alcohol reaction. Wien Clin Wochenschr 1957, Sept 27
Leshner, A. Addiction is a brain disease, and it matters. Science. 1997 278, 45-7.
Lewis M. The biology of desire. Why addiction is not a disease. New York. Public Affairs. 2015, passim
Liebson I, Bigelow G, Flame J. Alcoholism among methadone patients: a specific treatment method. Amer J Psychiat 1973;130:483-485
Liebson I, Faillace LA. The pharmacological reinforcement of disulfiram maintenance in chronic alcoholism. NIDA Research Monograph 1971 pp 1266-1273
Linden DE. How psychotherapy changes the brain--the contribution of functional neuroimaging. Mol Psychiatry. 2006 Jun;11(6):528-38.
Liversedge M. Beating truancy. Spectator, 15 July1978. 18
Lonardo A, Ballestri S, Romagnoli D, Nascimbeni F. Alcohol and Steatosis: The Japanese Paradox. EBioMedicine. 2016;8:23-24
Loudenburg R, Drube G, Leonardson G. South Dakota 24/7 Sobriety Program Evaluation Findings Report. Dakota: Mountain Plains Evaluation, LLC. 2010
Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A, Berner M, Wodarz N, Heinz A, Smolka MN, Zimmermann US, Wellek S, Kiefer F, Anton RF. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol. 2013 Nov;18(6):937-46.
Mark TL, Kranzler HR, Song X, et al. Physicians’ opinions about medications to treat alcoholism. Addiction 2003;98:617–26.
Martensen-Larsen O. Treatment of alcoholism with a sensitising drug, Lancet, 1948, 252, 1004-1005
Masson J.(Trans.and Ed.).The complete letters of Sigmund Freud to Wilhelm Fliess. Cambridge, MA: Belknap/Harvard. 1985 passim.
Mathew RJ, Georgi J, Nagy P. Substance Abuse Treatment: Beyond the Minnesota Model. North Carolina Med J 1994;55:224-6
McConville C, Tawari P, Wang W.Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection. Int J Pharm. 2015 Oct 15;494(1):73-82.
McNichol R, Ewing J, Faiman M. Disulfiram (Antabuse) A unique medical aid to sobriety. Springfield. Charles Thomas. 1987
Mechelli A, Crinion JT, Noppeney U, O'Doherty J, Ashburner J, Frackowiak RS, Price CJ.
Neurolinguistics: structural plasticity in the bilingual brain. Nature. 2004 Oct 14;431(7010):757.
Meier M, Woywodt A, Hoeper M. Acute liver failure: a message found under the skin Postgrad Med J 2005;81:269–270.
Miller L. Disulfiram-induced lead intoxication. Am J Psychiat 1993;150;7, 1130
Miller W, Hester R. In-patient alcoholism treatments: who benefits? Am Psychologist 1986;41:794-805.
Miller WR, Hester RK. The effectiveness of alcoholism treatment methods: what research reveals. In: Treating addictive behaviours: Processes of change. Miller, W. R., Heather, N .(Eds). New York: Plenum. 1986.
Miller WR. The effectiveness of alcoholism treatment modalities: causes and consequences of alcohol abuse. Hearings before the committee on governmental affairs, part III: US Senate. 1989:171-185
Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav. 1996 Nov-Dec;21(6):835-42.
Milton J, Solodkin A, Hlustík P, et al. (2007) The mind of expert motor performance is cool and focused. Neuroimage 35:804–13.
Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D. High-dose naltrexone therapy and dietary counselling for obesity. Biol Psychiatry 1987;22:35 – 42.
Moseley JB, O’Malley K, Petersen NJ, et al. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347:81-8.
Mukasa H, Arikawa K. A new double medication method for the treatment of alcoholism using the drug cyanamide. Kurume Med J 1968;15;3,137-43
Mukasa H, Ichihara T, Eto A. A new treatment of alcoholism with cyanamide Kurume Med J 1964;11;2,96-101
Murphy S, Hoffman A. 1993. An empirical description of phases of maintenance following treatment for alcohol dependence. J Subst Abuse, 5, 131-143.
Mutschler J, Bühler M, Grosshans M, Diehl A, Mann K, Kiefer F. Disulfiram, an option for the treatment of pathological gambling? Alcohol Alcohol. 2010 Mar-Apr;45(2):214-6.
Mutschler J, Grosshans M, Soyka M, Rösner S. Current findings and mechanisms of action of difulfiram in the treatment of alcohol dependence. Pharmacopsychiat. 2016;49;1-5
Nagai N, Yoshioka C, Mano Y, Ito Y, et al. Effect of Eye Drops Containing Disulfiram and Low- Substituted Methylcellulose in Reducing Intraocular Pressure in Rabbit Models. Curr Eye Res. 2014 Oct 20:1-11.
Najavitz L, Weiss R. Variations in therapist effectiveness in the treatment of patients with substance use disorders: an empiricial review. Addiction 1994;89:679-688.
Najlah M, Ahmed Z, Iqbal M, Wang Z, Tawari P, Wang W, McConville C. Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer. Eur J Pharm Biopharm. 2017 Mar;112:224-233. doi: 10.1016/j.ejpb.2016.11.032.
Newton-Howes G, Levack WM, McBride S, Gilmor M, Tester R. Non-physiological mechanisms influencing disulfiram treatment of alcohol use disorder: A grounded theory study. Drug Alc Depend 2016;165:126-31.
Ningaraj NS, Schloss JV, Williams TD, Faiman MD. Glutathione carbamoylation with S-methyl N,N-diethylthiolcarbamate sulfoxide and sulfone. Mitochondrial low Km aldehyde dehydrogenase inhibition and implications for its alcohol-deterrent action. Biochem Pharmacol. 1998; 55(6):749-56.
O’Farrell TJ, Bayog RD. Antabuse contracts for married alcoholics and their spouses: a method to maintain antabuse ingestion and decrease conflict about drinking. J Subst Abuse Treat1986;3:11-8.
Ocaranza P, Quintanilla ME, Tampier L, Karahanian E, Sapag A, Israel Y. Gene therapy reduces ethanol intake in an animal model of alcohol dependence. Alc Clin Exp Res. 2008 Jan;32(1):52-7.
Ochoa Mangado E, Arias Horcajadas F. Consumo de alcohol en dependientes de opiáceos en tratamiento con naltrexona. Actas Esp Psiquiatr 2000;28:239-249.
O’Farrell TJ. Treating alcohol problems: marital and family interventions. Guilford Press, New York 1993.
O'Farrell TJ, Choquette KA, Cutter HS. Couples relapse prevention sessions after behavioral marital therapy for male alcoholics: outcomes during the three years after starting treatment. J Stud Alcohol. 1998 Jul;59(4):357-70.
Öjehagen A, Berglund M. To keep the alcoholic in out-patient treatment: a differentiated approach through treatment contracts. Acta Psych Scand 1986;73;68-75
Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial. JAMA Psychiatry. 2015 May;72(5):430-7
Palmstierna T. A model for predicting alcohol withdrawal delirium. Psychiatr Serv. 2001 Jun;52(6):820-3.
Peteet JR, Brenner S, Curtiss D, Ferrigno M, Kauffman J. A stage of change approach to addiction in the medical setting. Gen Hosp Psychiat 1998 Sep;20(5):267-73.
Phillips M, Greenberg J. Dose-ranging study of depot disulfiram in alcohol abusers. Alc Clin Exp Res. 1992 Oct;16(5):964-7.
Phillips M. Persistent sensitivity to ethanol following a single dose of parenteral sustained-release disulfiram. Adv Alcohol Subst Abuse. 1987;7(1):51-61.
Poulsen HE, Ranek L, Jørgensen L. The influence of disulfiram on acetaminophen metabolism in man. Xenobiotica. 1991 Feb;21(2):243-9.
Poulson EH, Loft S, Andersen JR, Andersen M. Disulfiram therapy – adverse drug reactions and interactions. Acta Psychiat Scand 1992;86:59-66.
Project MATCH Research Group. Therapist Effects in Three Treatments for Alcohol Problems Psychother Res 1998;8,4,
Reisfield GM, Goldberger BA, Pesce AJ, Crews BO, Wilson GR, Teitelbaum SA, Bertholf RL. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after intensive exposure to high ethanol content mouthwash. J Anal Toxicol. 2011 Jun;35(5):264-8.
Rivera-Meza M, Quintanilla ME, Tampier L. Reduction of ethanol consumption in alcohol-preferring rats by dual expression gene transfer. Alcohol Alcohol. 2012 Mar-Apr;47(2):102-8
Roizen R, Fillmore KM. Some notes on the new paradigmatic environment of "natural remission" studies in alcohol research. Subst Use Misuse. 2001 Sep;36(11):1443-65.
Ross JS, Tkach J, Ruggieri PM, et al. (2003) The mind’s eye: functional MR imaging evaluation of golf motor imagery. Am J Neuroradiol 24:1036–44.
Salvato FR, Mason B. Changes in transaminases over the course of a twelve-week, double blind nalmefene trial in a 38-year old female subject. Alcohol Clin Exp Res 1994;18:1187-9
Santos T, Martins Campos A, Morais H. Sensory-motor axonal polyneuropathy involving cranial nerves: An uncommon manifestation of disulfiram toxicity. Clin Neurol Neurosurg. 2017 Jan;152:12-15. doi: 10.1016/j.clineuro.2016.11.005. Epub 2016 Nov 10.
Saunders B. Treatment does not work: some criteria of failure. In: The misuse of alcohol: crucial issues in dependence, treatment and prevention. Heather N, Robertson I, Davies P (Eds): London: Croom Helm 1985:102-116.
Sereny G, Sharma V, Holt J, Gordis E. Mandatory supervised Antabuse therapy in an out-patient alcoholism program: a study. Alc Clin Exper Res 1986;10:290-292.
Shepherd JP. Criminal deterrence as a public health strategy. Lancet 2001; 358:1717–22.
Siemens W1, Xander C, Meerpohl JJ, Antes G, Becker G. Drug treatments for pruritus in adult palliative care. Dtsch Arztebl Int. 2014 Dec 12;111(50):863-70. doi: 10.3238/arztebl.2014.0863.
Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006 Jul 1;333(7557):15. Epub 2006 Jun 21.
Sisson R, Azrin N. Family member involvement to initiate and promote treatment of problem drinkers. J Behav Ther Exper Psychiat 1986;17, 15-21.
Skinner, MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta analysis. Plos One 2014, 9(2): e87366
Sloane R, Staples F, Cristol A, Yorkston N, Whipple K. Psychotherapy versus Behaviour Therapy. Cambridge, MA. Harvard University Press. 1975, passim
Smith W. Lecture to New York Medical Society, 1958. Brown University Digest of Addiction Theory and Application, 13, (5) May 1994, p 12.
Sobell LC, Klingemann HK, Toneatto T, Sobell MB, Agrawal S, Leo GI. Alcohol and drug abusers' perceived reasons for self-change in Canada and Switzerland: computer-assisted content analysis. Subst Use Misuse. 2001 Sep;36(11):1467-500.
Special Committee Of The Royal College Of Psychiatrists. Alcohol: our favourite drug. Tavistock Publications, London 1986
Spiegel DR, McCroskey A, Puaa K, Meeker G, Hartman L, Hudson J, Hung YC. A Case of Disulfiram-Induced Psychosis in a Previously Asymptomatic Patient Maintained on Mixed Amphetamine Salts: A Review of the Literature and Possible Pathophysiological Explanations. Clin Neuropharmacol. 2016 Sep-Oct;39(5):272-5. doi: 10.1097/WNF.0000000000000166.
Stowell A, Johnsen J, Ripel A, Mørland J. Diphenhydramine and the calcium carbimide-ethanol reaction: a placebo-controlled clinical study. Clin Pharmacol Ther. 1986 May;39(5):521-5.
Su K-C, Nguyen L, Rogers C. Deaths in Unlicensed Alcohol Rehabilitation Facilities. J Forensic Sci, January 2017, Vol. 62, No. 1 doi: 10.1111/1556-4029.13253
Suh JJ, Helen M. Pettinati HM, Kampman K, and Charles P. O’Brien CP. The status of disulfiram a half of a century later. J Clin Psychopharmacol 2006:26;3, 290-302
Sun F, Tsuritani I, Yamada Y. (2002) Contribution of genetic polymorphisms in ethanol-metabolizing enzymes to problem drinking behavior in middle-aged Japanese men. Behav Genet 32:229–36.
Swift RM. Medications and alcohol craving. Alcohol Res Health. 1999;23(3):207-13.
Tawari PE, Wang Z, Najlah M, et al The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells. Toxicol Res (Camb). 2015 Nov 19;4(6):1439-1442.
Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis: a crossover, double blind, placebo controlled study. J Hepatol 2002. 37(6): 717-722.
Thase ME, Larsen KG, Kennedy SH. Assessing the ‘true’ effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model Brit J Psychiat .2011, 199 (6) 501-507
Thorens G, Manghi R, Khan R, et al. Le disulfirame, un traitement? Soyons logique. Deuxieme partie: Le disulfirame, peut-il être considéré comme un traitement psychologique? [Is disulfiram really a treatment? Let’s be logical. Part 2. Can disulfiram be considered a psychological treatment?] Rev Med Suisse 2010;10:584–7.
Thyssen JP, Menné T. Metal allergy--a review on exposures, penetration, genetics, prevalence, and clinical implications. Chem Res Toxicol. 2010 Feb 15;23(2):309-18. doi: 10.1021/tx9002726.
Treatment of Alcohol Abuse: An Evidence-Based Review. Alc Clin Exp Res. 27:1645-1656, 2003)
van Zyl P. Doctors' views of disulfiram and their response to relapse in alcohol-dependent patients, Free State, 2009. Afr J Prim Health Care Fam Med. 2016 Jun 17;8(1):1-7
Volkow N., Li T. Drugs and alcohol: treating and preventing abuse, addiction and their medical consequences. Pharmacol Ther. 2005 108, 3-17.
Volkow, N.D., Wang, G.J., Fowler, J.S., Tomasi, D., Telang, F., and Baler, R. Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain’s control circuit. Bioessays 32(9):748–755, 2010.
Walton MA, Castro FG, Barrington EH. The role of attributions in abstinence, lapse, and relapse following substance abuse treatment. Addict Behav. 1994 May-Jun;19(3):319-31.
Wang Z, Tan J, McConville C, et al Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine. 2016 Aug 10;13(2):641-657.
Wetterling T, Weber B, Depfenhart M, Schneider B, Junghanns K. Development of a rating scale to predict the severity of alcohol withdrawal syndrome. Alcohol Alcohol. 2006 Nov-Dec;41(6):611-5
Williams E, Gupta S, Rubinsky A, Glass J, Jones-Webb R, Bensley K, Harris A. Variation in receipt of pharmacotherapy for alcohol use disorders across racial/ethnic groups: A national study in the U.S. Veterans Health Administration. Drug Alcohol Depend. 2017 Jul 11;178:527-533.
Williams E. Effects of alcohol on workers with carbon disulfide, J Am Med Assoc 1937;109, 1472-3
Yamauchi M, Kimura T, Takeda K, Sakamoto K, Ohata M, Tabe T, Nakano K, Fujiwara S, Takao Y, Toda G. Ethanol patch test: a simple method for identifying the effectiveness of cyanamide in alcoholics. Alc Clin Exp Res. 2000 Apr;24(4 Suppl):39S-42S.
Zala D, Schmid M, Buhler H. Fulminante hepatitis durch disulfiram. Deutsche Med Wochenschr 1993;118;1355-60
Zullino D, Wullschleger A, Thorens G, et al. Le disulfirame, un traitement? Soyons logique. Premiere partie: Le disulfirame, peut-il être considéré comme un traitement phamacologique? [Is disulfiram really a treatment? Let’s be logical. Can disulfiram be considered a pharmacological treatment?] Part 1. Rev Med Suisse 2010:10:565–7.